Ukrainian Journal of Perinatology and Pediatrics. 2024.4(100): 29-34. doi: 10.15574/PP.2024.4(100).2934
Demianiuk S. V.
National Pirogov Memorial Medical University, Vinnytsya, Ukraine

For citation: Demianiuk SV. (2024). The significance of thrombophilia as a risk factor of fetal loss syndrome. Ukrainian Journal of Perinatology and Pediatrics. 4(100): 29-34. doi: 10.15574/PP.2024.4(100).2934.
Article received: Sep 09, 2024. Accepted for publication: Nov 27, 2024.

Despite significant advancements in modern obstetrics in understanding the factors contributing to perinatal loss and associated pathologies, the role of hemostatic disorders in pregnant women remains insufficiently studied.
Aim – to study the frequency and spectrum of thrombophilic disorders in patients with fetal loss syndrome (FLS).
Materials and methods. A retrospective cohort study was conducted involving 83 women of reproductive age (21 to 42 years; mean age: 30.86±5.02 years) with a history of fetal loss syndrome who sought medical care at obstetric and gynecological hospitals in Vinnytsia between 2017 and 2022. Reproductive function was studied: age at menarche, somatic, gynecological, and obstetric history, and the results of thrombophilia gene polymorphism studies. Genetic forms of thrombophilia were identified using the polymerase chain reaction (PCR) method. Statistical analysis of the data was performed using the "SPSS 21" software.

• Thrombophilia was identified in the majority of patients with fetal loss syndrome (66.3%), accounting for 63.3% of cases in patients with early miscarriages, 65% in late miscarriages, and 66.7% in cases of antenatal or early neonatal fetal death. The most common forms of thrombophilia in patients with FLS included heterozygous polymorphism of PAI-1 (43.6%), circulating antiphospholipid antibodies (34.5%), heterozygous mutation of Factor V (14.5%), and fibrinogen polymorphism (14.5%). It was determined that the most common form of thrombophilia among women with early miscarriages was antiphospholipid syndrome, whereas in women with late miscarriages, genetic forms of thrombophilia predominated.
• Given the pathogenic role of genetic and acquired defects in the hemostatic system in the development of reproductive losses, women with a history of fetal loss syndrome should be screened for thrombophilia.

The research was carried out in accordance with the principles of the Helsinki Declaration. The study protocol was approved by the Local Ethics Committee of participating institution. The informed consent of the patient was obtained for conducting the studies.
No conflict of interest was declared by the author.
Keywords: thrombophilia, antiphospholipid syndrome, polymorphism, fetal loss syndrome, miscarriage, early miscarriages, pregnancy, risk factors.

REFERENCES

1. Alecsandru D, Klimczak AM, Garcia Velasco JA, Pirtea P, Franasiak JM. (2021). Immunologic causes and thrombophilia in recurrent pregnancy loss. Fertil Steril. 115(3): 561-566. https://doi.org/10.1016/j.fertnstert.2021.01.017; PMid:33610320

2. Athar A, Kashyap P, Khan S, Sattar RSA, Khan SA, Prasad S et al. (2024). Genetic landscape of thrombophilia in recurrent miscarriages. Obstet Gynecol Sci. 67(5): 435-448. https://doi.org/10.5468/ogs.22084; PMid:39069307 PMCid:PMC11424186

3. Bramham K, Hunt BJ, Germain S, Calatayud I, Khamashta M, Bewley S, Nelson-Piercy C. (2010). Pregnancy outcome in different clinical phenotypes of antiphospholipid syndrome. Lupus. 19(1): 58-64. https://doi.org/10.1177/0961203309347794; PMid:19897518

4. Dizon-Townson D, Miller C, Sibai B, Spong CY, Thom E, Wendel G Jr et al. (2005). The relationship of the factor V Leiden mutation and pregnancy outcomes for mother and fetus. Obstet Gynecol. 106(3): 517-524. https://doi.org/10.1097/01.AOG.0000173986.32528.ca; PMid:16135581

5. Dubossarskaya ZM, Dukа YM. (2011). Place of thrombophilia in structure of the syndrome of pregnancy loss. Tavrycheskyi medytsynsko-byolohycheskyi vestnyk. 14(3): 75-77.

6. Eslami MM, Khalili M, Soufizomorrod M, Abroun S, Razi B. (2020). Factor V Leiden 1691G > A mutation and the risk of recurrent pregnancy loss (RPL): systematic review and meta-analysis. Thromb J. 18: 11. https://doi.org/10.1186/s12959-020-00224-z; PMid:32595420 PMCid:PMC7313225

7. Floridon C, Nielsen O, Hølund B, Sweep F, Sunde L, Thomsen SG, Teisner B. (2000). Does plasminogen activator inhibitor-1 (PAI-1) control trophoblast invasion? A study of fetal and maternal tissue in intrauterine, tubal and molar pregnancies. Placenta. 21(8): 754-762. https://doi.org/10.1053/plac.2000.0573; PMid:11095924

8. Frikha R, Turki F, Abdelmoula N, Rebai T. (2023). Maternal inherited thrombophilia and recurrent pregnancy loss: a Tunisian study and review of literature. Afr Health Sci. 23(4): 482-486. https://doi.org/10.4314/ahs.v23i4.52; PMid:38974294 PMCid:PMC11225465

9. Kovacheva K, Ivanov P, Konova E, Simeonova M, Komsa-Penkova R. (2007). Genetic thrombophilic defects (Factor V Leiden, prothrombin G20210A, MTHFR C677T) in women with recurrent fetal loss. Akush Ginekol (Sofiia). 46(7): 10-16.

10. Kovalevsky G, Gracia CR, Berlin JA, Sammel MD, Barnhart KT. (2004). Evaluation of the association between hereditary thrombophilias and recurrent pregnancy loss: a meta-analysis. Arch Intern Med. 164(5): 558-563. https://doi.org/10.1001/archinte.164.5.558; PMid:15006834

11. Kutteh WH, Triplett DA. (2006). Thrombophilias and recurrent pregnancy loss. Semin Reprod Med. 24(1): 54-66. https://doi.org/10.1055/s-2006-931801; PMid:16418978

12. Liu X, Chen Y, Ye C, Xing D, Wu R, Li F et al. (2021). Hereditary thrombophilia and recurrent pregnancy loss: a systematic review and meta-analysis. Hum Reprod. 36(5): 1213-1229. https://doi.org/10.1093/humrep/deab010; PMid:33575779

13. Maghsudlu M, Noroozi Z, Zokaei E, Motevaseli E. (2024). Systematic review and meta-analysis of association between plasminogen activator inhibitor-1 4G/5G polymorphism and recurrent pregnancy loss: an update. Thromb J. 22(1): 44. https://doi.org/10.1186/s12959-024-00612-9; PMid:38807142 PMCid:PMC11134946

14. Practice Committee of the American Society for Reproductive Medicine. (2012). Evaluation and treatment of recurrent pregnancy loss: a committee opinion. Fertil Steril. 98(5): 1103-1111. https://doi.org/10.1016/j.fertnstert.2012.06.048; PMid:22835448

15. Preston FE, Rosendaal FR, Walker ID, Briët E, Berntorp E, Conard J et al. (1996). Increased fetal loss in women with heritable thrombophilia. Lancet. 348(9032): 913-916. https://doi.org/10.1016/S0140-6736(96)04125-6; PMid:8843809

16. Rey E, Kahn SR, David M, Shrier I. (2003). Thrombophilic disorders and fetal loss: a meta-analysis. Lancet. 361(9361): 901-908. https://doi.org/10.1016/S0140-6736(03)12771-7; PMid:12648968

17. Roqué H, Paidas MJ, Funai EF, Kuczynski E, Lockwood CJ. (2004). Maternal thrombophilias are not associated with early pregnancy loss. Thromb Haemost. 91(2): 290-295. https://doi.org/10.1160/TH03-09-0596; PMid:14961156

18. Silver RM, Zhao Y, Spong CY, Sibai B, Wendel G Jr, Wenstrom K et al. (2010). Prothrombin gene G20210A mutation and obstetric complications. Obstet Gynecol. 115(1): 14-20. https://doi.org/10.1097/AOG.0b013e3181c88918; PMid:20027028 PMCid:PMC2981703

19. Soto-Peleteiro A, Gonzalez-Echavarri C, Ruiz-Irastorza G. (2024). Obstetric antiphospholipid syndrome. Med Clin (Barc). 163; Suppl 1: S14-S21. https://doi.org/10.1016/j.medcli.2024.05.001; PMid:39174149

20. Stevens SM, Woller SC, Bauer KA, Kasthuri R, Cushman M, Streiff M et al. (2016). Guidance for the evaluation and treatment of hereditary and acquired thrombophilia. J Thromb Thrombolysis. 41(1): 154-164. https://doi.org/10.1007/s11239-015-1316-1; PMid:26780744 PMCid:PMC4715840

21. Wu O, Robertson L, Twaddle S, Lowe GD, Clark P, Greaves M et al. (2006). Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study. Health Technol Assess. 10(11): 1-110. https://doi.org/10.3310/hta10110; PMid:16595080

22. Yelnik CM, Lambert M, Drumez E, Le Guern V, Bacri JL, Guerra MM et al. (2018). Bleeding complications and antithrombotic treatment in 264 pregnancies in antiphospholipid syndrome. Lupus. 27(10): 1679-1686. https://doi.org/10.1177/0961203318787032; PMid:30016929

23. Youssef A, Vermeulen N, Lashley EELO, Goddijn M, van der Hoorn MLP. (2019). Comparison and appraisal of (inter)national recurrent pregnancy loss guidelines. Reprod Biomed Online. 39(3): 497-503. https://doi.org/10.1016/j.rbmo.2019.04.008; PMid:31182358

24. Zhuk SI, Us IV, Atamanchuk IM. (2012). Thrombophilias and miscarriage: a modern view of the problem. Health of Ukraine. 4(8): 28.